DE602007006663D1 - Verfahren zur behandlung von krebs - Google Patents

Verfahren zur behandlung von krebs

Info

Publication number
DE602007006663D1
DE602007006663D1 DE602007006663T DE602007006663T DE602007006663D1 DE 602007006663 D1 DE602007006663 D1 DE 602007006663D1 DE 602007006663 T DE602007006663 T DE 602007006663T DE 602007006663 T DE602007006663 T DE 602007006663T DE 602007006663 D1 DE602007006663 D1 DE 602007006663D1
Authority
DE
Germany
Prior art keywords
cancer
mammal
treatment
oleandomycin
tylosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006663T
Other languages
English (en)
Inventor
Rina Rosin-Arbesfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE602007006663D1 publication Critical patent/DE602007006663D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE602007006663T 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs Active DE602007006663D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81260506P 2006-06-12 2006-06-12
PCT/IL2007/000706 WO2007144876A1 (en) 2006-06-12 2007-06-12 Methods for treating cancer

Publications (1)

Publication Number Publication Date
DE602007006663D1 true DE602007006663D1 (de) 2010-07-01

Family

ID=38541966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006663T Active DE602007006663D1 (de) 2006-06-12 2007-06-12 Verfahren zur behandlung von krebs

Country Status (7)

Country Link
US (1) US9486467B2 (de)
EP (1) EP2029147B1 (de)
JP (1) JP2009539970A (de)
CN (1) CN101568343A (de)
AT (1) ATE468119T1 (de)
DE (1) DE602007006663D1 (de)
WO (1) WO2007144876A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934548A2 (de) 2012-12-24 2015-10-28 Ramot at Tel-Aviv University Ltd Mittel zur behandlung von genetischen erkrankungen infolge von unsinnigen mutationen und verfahren zur identifizierung davon
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
CN110709408B (zh) * 2017-02-22 2022-10-25 Isr免疫系统调节控股公共有限公司 新型免疫刺激大环内酯
CN110545820B (zh) * 2017-04-06 2023-01-10 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
ES2912734T3 (es) * 2017-07-04 2022-05-27 Shenyang Fuyang Pharmaceutical Tech Co Ltd Uso de isovaleril espiramicina I o III en la preparación de fármaco para tratar y/o prevenir el tumor y fármaco
RU2768583C2 (ru) * 2018-01-19 2022-03-24 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Ингибитор мишени рапамицина в клетках млекопитающих, фармацевтическая композиция и их применение
KR20200112898A (ko) 2018-01-19 2020-10-05 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 캐리마이신 또는 이의 활성 성분의 용도
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
WO2023114231A1 (en) * 2021-12-14 2023-06-22 The Regents Of The University Of California Clustered mutations for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092473A (en) 1975-08-01 1978-05-30 Sanraku Ocean Co., Ltd. Tylosin derivatives and their manufacturing process
GB1540397A (en) 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
US4064143A (en) 1976-12-10 1977-12-20 Pfizer Inc. Oleandomycin derivatives
US4205163A (en) 1977-11-08 1980-05-27 Sanraku-Ocean Co., Ltd. Tylosin derivatives
US4124755A (en) 1978-01-03 1978-11-07 Pfizer Inc. 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
SE445739B (sv) 1978-09-14 1986-07-14 Toyo Jozo Kk 3", 4"-diacyltylosinderivat
US4429116A (en) 1982-12-27 1984-01-31 Pfizer Inc. Alkylated oleandomycin containing compounds
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
ATE284213T1 (de) * 1996-07-08 2004-12-15 Galderma Res & Dev Apoptose induzierende adamantyl-derivate und deren verwendung als antikrebsmittel
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
HRP980646B1 (en) 1998-12-30 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Novel oleandomycin derivatives
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
EE200100613A (et) 1999-05-24 2003-02-17 Pfizer Products Inc. 13-metüülerütromütsiini derivaadid
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20050171032A1 (en) 2002-04-11 2005-08-04 Children's Medical Center Corporation Methods for the treatment of cancer
CN1562066A (zh) 2004-04-14 2005-01-12 山东鲁抗舍里乐药业有限公司 酒石酸泰乐菌素颗粒剂及其制备方法
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products

Also Published As

Publication number Publication date
US20110306571A1 (en) 2011-12-15
EP2029147A1 (de) 2009-03-04
ATE468119T1 (de) 2010-06-15
CN101568343A (zh) 2009-10-28
US9486467B2 (en) 2016-11-08
WO2007144876A1 (en) 2007-12-21
EP2029147B1 (de) 2010-05-19
JP2009539970A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
DE602007006663D1 (de) Verfahren zur behandlung von krebs
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
RS52956B (en) CANCER TREATMENT COMPOSITIONS
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
PL374191A1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
BRPI0715845A2 (pt) Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
WO2008024977A3 (en) Isoquinoline, quinazoline and phthalazine derivatives
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
MX2009001072A (es) Proceso de sintesis de macrolido.
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
UA98303C2 (ru) Способ синтеза макролидов
MY149028A (en) Nalmefene hydrochloride dihydrate
WO2007149782A3 (en) Selective inhibitors for transferases
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
WO2007060627A3 (en) Use of macrolide derivatives for treating acne
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BRPI0916885B8 (pt) composição farmacêutica
BRPI0917245B8 (pt) compostos derivados de isoquinolinona e sua composição farmacêutica

Legal Events

Date Code Title Description
8364 No opposition during term of opposition